Cormorant Asset Management, LLC Insider Profile
25 Followers
Cormorant Asset Management, LLC, Former 10% Owner at Corbus Pharmaceuticals, holds 1.92M shares in Corbus Pharmaceuticals (Ticker: CRBP), holds 8.27M shares in EyePoint Pharmaceuticals (Ticker: EYPT), holds 0.00 shares in OnKure Therapeutics (Ticker: OKUR). Most recently, Cormorant Asset Management, LLC Sold ― shares of Corbus Pharmaceuticals on Nov 02, 2026 for an estimated value of $1.74M.
Cormorant Asset Management, LLC's Trading History
| CRBPCorbus Pharmaceuticals | Nov 02, 2026 | Former 10% Owner | Informative Sell | 1.74M | $6.51M | |
| EYPTEyePoint Pharmaceuticals | Dec 08, 2025 | Former 10% Owner | Informative Sell | 942.00K | $2.53M | |
| OKUROnKure Therapeutics | May 19, 2025 | Former 10% Owner | Informative Sell | 3.35M | $0.00 | |
| BIOABioAge Labs, Inc. | Oct 01, 2024 | Former 10% Owner | Uninformative Buy | ― | $9.04M | |
| IMRXImmuneering | Apr 03, 2024 | Ten Percent Owner | Informative Sell | 1.16M | $10.74M | |
| AMAMAmbrx Biopharma | Oct 25, 2023 | ― | Informative Buy | 9.14M | $314.47M | |
| GRNAGreenLight Biosciences Holdings | Jul 24, 2023 | ― | Uninformative Sell | ― | $0.00 | |
| VIGLVigil Neuroscience Inc | Jan 13, 2022 | ― | Uninformative Buy | ― | $4.97M | |
| VTYXVentyx Biosciences | Oct 27, 2021 | ― | Uninformative Buy | ― | $19.74M | |
| PYXSPyxis Oncology | Oct 15, 2021 | Former 10% Owner | Uninformative Buy | ― | $1.77M | |
| TYRATyra Bioscience | Sep 21, 2021 | Former 10% Owner | Uninformative Buy | ― | $21.43M | |
| ICVXIcosavax | Aug 04, 2021 | ― | Uninformative Buy | ― | $6.53M | |
| JBIOJade Biosciences | Jul 07, 2021 | Former 10% Owner | Uninformative Buy | ― | $32.78M | |
| ELEVElevation Oncology | Jul 01, 2021 | ― | Uninformative Buy | ― | $815.11K | |
| GLUEMonte Rosa Therapeutics | Jun 30, 2021 | Former 10% Owner | Informative Buy | 11.40M | $30.00M | |
| VERVVerve Therapeutics | Jun 23, 2021 | ― | Uninformative Buy | ― | $10.95M | |
| ~RAINRain Oncology | Apr 29, 2021 | ― | Uninformative Buy | ― | $3.36M | |
| DSGNDesign Therapeutics | Apr 01, 2021 | Former 10% Owner | Uninformative Buy | ― | $53.55M | |
| RXDXPrometheus Biosciences | Mar 18, 2021 | ― | Uninformative Buy | ― | $444.43M | |
| BCABBioAtla | Dec 22, 2020 | Former 10% Owner | Uninformative Buy | ― | $3.58M | |
| OLMAOlema Pharmaceuticals | Nov 23, 2020 | Former 10% Owner | Uninformative Buy | ― | $24.73M | |
| AVIRAtea Pharmaceuticals | Nov 05, 2020 | Former 10% Owner | Uninformative Buy | ― | $27.57M | |
| RNAMAvidity Biosciences | Jun 18, 2020 | ― | Informative Buy | 5.40M | $183.11M | |
| TPTXTurning Point Therapeutics | Apr 25, 2019 | ― | Informative Buy | 7.20M | $237.33M | |
| ~AXNXAxonics Modulation Technologies | Nov 02, 2018 | ― | Informative Buy | 2.00M | $133.86M | |
| KZRKezar Life Sciences | Jun 27, 2018 | ― | Informative Buy | 3.75M | $13.77M | |
| KNSAKiniksa Pharmaceuticals | May 31, 2018 | Ten Percent Owner | Informative Buy | 1.25M | $166.79M | |
| KANTKineta | Dec 18, 2017 | ― | Informative Buy | 2.46M | $1.11M | |
| CLRBCellectar Biosciences | Sep 05, 2014 | Ten Percent Owner | Informative Buy | ― | $604.20K | |
| BMEABiomea Fusion | ― | Director, Ten Percent Owner | ― | ― |
You May Also Like
Cormorant Asset Management, LLC insider profile FAQ
What is the percentage of profitable transactions made by Cormorant Asset Management, LLC?
The percentage of profitable transactions made by Cormorant Asset Management, LLC is 24%.
What is the average return per transaction made by Cormorant Asset Management, LLC?
The average return per transaction made by Cormorant Asset Management, LLC is -27.50%.
What stocks does Cormorant Asset Management, LLC hold?
Cormorant Asset Management, LLC holds: CRBP, EYPT, CLRB, KANT, KNSA, KZR, ~AXNX, TPTX, RNAM, AVIR, OLMA, BCAB, RXDX, DSGN, OKUR, BMEA, ~RAIN, GRNA, VERV, AMAM, GLUE, ELEV, JBIO, ICVX, IMRX, TYRA, PYXS, VTYX, VIGL, BIOA stocks.
What was Cormorant Asset Management, LLC’s latest transaction?
Cormorant Asset Management, LLC’s latest transaction was an Informative Sell of $1.74M.
What was Cormorant Asset Management, LLC's most profitable transaction?
Cormorant Asset Management, LLC’s most profitable transaction was an Informative Buy of AMAM stock on March 16, 2023. The return on the trade was 176.40%.
What is Cormorant Asset Management, LLC's role in Corbus Pharmaceuticals?
Cormorant Asset Management, LLC's role in Corbus Pharmaceuticals is Former 10% Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.